AMPH Pemfailan SEC - Amphastar Pharmaceuticals, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	54930055TH0ZLSAQMJ38
CIK	1297184

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amphastar Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

August 12, 2025	EX-99.1	Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Exhibit 99.1 Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA – August 12, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar”), a biopharmaceutical company focused o
August 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 8, 2025 Amphastar Pharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 8, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
August 7, 2025	EX-3.1	Amended and Restated Certificate of Incorporation of Amphastar Pharmaceuticals, Inc, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMPHASTAR PHARMACEUTICALS, INC. Amphastar Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: A. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on May 19, 2004.
August 7, 2025	EX-10.1	Second Amendment to the Contract Manufacturing Agreement by and between Amphastar Nanjing Pharmaceutical, Inc., and Nanjing Hanxin Pharmaceutical Technology Co., Ltd, dated May 13, 2025 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(
August 7, 2025	EX-10.2	First Amendment to the Contract Research Agreement by and between Amphastar Pharmaceuticals, Inc., and Nanjing Hanxin Pharmaceutical Technology Co., Ltd., dated May 7, 2025 Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2025 Amphastar Pharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
August 7, 2025	EX-99.1	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9 million, or $0.85 per share, for the second quarter - Company to hold a conference call today
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH
July 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): July 18, 2025 Amphastar Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): July 18, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi
June 4, 2025	EX-3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Amphastar Pharmaceuticals, Inc. (Forum Selection Provision) Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMPHASTAR PHARMACEUTICALS, INC. Amphastar Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1.The name of the Corporation is Amphastar Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was
June 4, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2025 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis
June 4, 2025	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Amphastar Pharmaceuticals, Inc. (Officer Exculpation) Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMPHASTAR PHARMACEUTICALS, INC. Amphastar Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1.The name of the Corporation is Amphastar Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was
June 4, 2025	EX-3.3	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the SEC on June 4, 2025) Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF AMPHASTAR PHARMACEUTICALS, INC. (initially adopted on March 24, 2014) (as amended on February 23, 2023 and February 25, 2025) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES‌1 1.1REGISTERED OFFICE‌1 1.2OTHER OFFICES‌1 ARTICLE II - MEETINGS OF STOCKHOLDERS‌1 2.1PLACE OF MEETINGS‌1 2.2ANNUAL MEETING‌1 2.3SPECIAL MEETING‌1 2.4ADVANCE NOTICE PROCEDURES‌2
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP
May 7, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 7, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission
May 7, 2025	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA – May 7, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2025. First Quarter Highlights ● Net
April 14, 2025	DEF 14A	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi
April 14, 2025	DEFA14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻Definitive Pr
April 2, 2025	PRE 14A	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ⌧ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defi
March 3, 2025	EX-19.1	Amphastar Pharmaceuticals, Inc. Insider Trading Policy, adopted on December 31, 2024 Exhibit 19.1 AMPHASTAR PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Adopted on December 31, 2024) A. POLICY OVERVIEW Amphastar Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Compan
March 3, 2025	EX-21.1	Subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Amphastar Medication Co., LLC California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Amphastar
March 3, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals,
February 27, 2025	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024 Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA – February 27, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended Decembe
February 27, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 27, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509
November 7, 2024	EX-10.1	Distribution Agreement by and between Armstrong Pharmaceuticals, Inc. and Hong Kong Genreach Limited, dated August 28, 2024 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(
November 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 6, 2024 Amphastar Pharma UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 6, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi
November 6, 2024	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA – November 6, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2024. Third quarter
August 30, 2024	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 28, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commis
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH
August 7, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
August 7, 2024	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA – August 7, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2024. Second Quarter Highlights ● Net
June 4, 2024	EX-10.1	2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc. (as amended and restated) Exhibit 10.1 AMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN (As amended and restated by the Board on February 26, 2024, subject to, and contingent upon, stockholder approval at the 2024 annual meeting of the Company’s stockholders ) 1.Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ●
June 4, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis
June 4, 2024	EX-99.1	Amphastar Announces Additional $50 Million Increase to its Share Buyback Program Exhibit 99.1 Amphastar Announces Additional $50 Million Increase to its Share Buyback Program RANCHO CUCAMONGA, Calif., June 4, 2024 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) today announced that on June 3, 2024, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The prima
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP
May 10, 2024	EX-10.1	Syndicated Loan Agreement dated January 17, 2024, by and between Amphastar Nanjing Pharmaceuticals, Co., Ltd. and Commercial Bank of China Limited in the original sum of approximately $40,000,000 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 10, 2024) Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Syndicated Loan Contract [Amphastar Nanjing Pharmaceuticals Inc.] (As the Borrower) [Nanjing Branch of Industrial and Commercial Bank of China Limited] (As the Lead Bank) [Na
May 8, 2024	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA – May 8, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2024. First Quarter Highlights ● Net
May 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 8, 2024 Amphastar Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 8, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission
April 19, 2024	DEFA14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin
April 12, 2024	DEFA14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻Definitive Pr
April 12, 2024	DEF 14A	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi
March 6, 2024	SC 13G/A	AMPH / Amphastar Pharmaceuticals, Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Fili
February 29, 2024	EX-97.1	Compensation Recovery Policy of the Company Exhibit 97.1 Amphastar Pharmaceuticals, Inc. COMPENSATION RECOVERY POLICY As adopted on August 4, 2023 Amphastar Pharmaceuticals, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Co
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals,
February 29, 2024	EX-21.1	Subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Amphastar Medication Co., LLC California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Amphastar
February 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amphastar Pharmaceuticals, Inc.
February 29, 2024	EX-99.33	Seventh Amendment to the Supply Agreement by and between MannKind Corporation and Amphastar Pharmaceuticals, Inc., dated December 22, 2023 Exhibit 10.33 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SEVENTH AMENDMENT TO SUPPLY AGREEMENT This seventh amendment ("Seventh Amendment") to the Supply Agreement by and between MannKind Corporation ("MannKind") and Amphastar Pha
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 28, 2024 Amphastar Pharm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 28, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm
February 28, 2024	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023 Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023 RANCHO CUCAMONGA, CA – February 28, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended Decembe
February 13, 2024	SC 13G/A	AMPH / Amphastar Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0281-amphastarpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Amphastar Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate
February 9, 2024	SC 13G/A	AMPH / Amphastar Pharmaceuticals, Inc. / Zhang Jack Y. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate
January 17, 2024	SC 13G/A	AMPH / Amphastar Pharmaceuticals, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 amph1566-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2023 (Date
November 8, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 8, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509
November 8, 2023	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023 Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA – November 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2023. Third Quarter
September 15, 2023	EX-10.1	Purchase Agreement, dated September 12, 2023, among Amphastar Pharmaceuticals, Inc. and Jefferies LLC, J.P. Morgan Securities LLC, Wells Fargo Securities LLC and BofA Securities Inc. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 15, 2023) Exhibit 10.1 $300,000,000 2.00% Convertible Senior Notes due 2029 Amphastar Pharmaceuticals, Inc. PURCHASE AGREEMENT September 12, 2023 Jefferies LLC J.P. Morgan Securities LLC Wells Fargo Securities, LLC BofA Securities, Inc. As Representatives of the several Initial Purchasers c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York
September 15, 2023	EX-4.1	Indenture, dated September 15, 2023, between Amphastar Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 15, 2023) Exhibit 4.1 AMPHASTAR PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 15, 2023 2.00% Convertible Senior Notes due 2029 i TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions‌1 Section 1.02. References to Interest‌13 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designat
September 15, 2023	EX-99.1	2 Exhibit 99.1 Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes RANCHO CUCAMONGA, CA – September 11, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar”) today announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 (the
September 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): September 11, 2023 Amphastar Phar UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): September 11, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Com
September 15, 2023	EX-99.2	2 Exhibit 99.2 Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes RANCHO CUCAMONGA, CA – September 13, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar”) today announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably belie
August 16, 2023	EX-99.2	Baqsimi® (glucagon) (A Product of Eli Lilly and Company) Unaudited Abbreviated Financial Statements As of March 31, 2023 and December 31, 2022 and for the Three Months Ended March 31, 2023 and 2022 Exhibit 99.2 Baqsimi® (glucagon) (A Product of Eli Lilly and Company) Unaudited Abbreviated Financial Statements As of March 31, 2023 and December 31, 2022 and for the Three Months Ended March 31, 2023 and 2022 Index to Abbreviated Financial Statements (Unaudited) Abbreviated Financial Statements (Unaudited) Statements of Assets Acquired‌3 Statements of Revenues and Direct Expenses‌4 Notes to Abbr
August 16, 2023	EX-99.1	Baqsimi® (glucagon) (A Product of Eli Lilly and Company) Abbreviated Financial Statements As of and for the Years Ended December 31, 2022 and 2021 (With Report of Independent Auditors) Exhibit 99.1 Baqsimi® (glucagon) (A Product of Eli Lilly and Company) Abbreviated Financial Statements As of and for the Years Ended December 31, 2022 and 2021 (With Report of Independent Auditors) Index to Abbreviated Financial Statements Report of Independent Auditors‌3 Abbreviated Financial Statements Statements of Assets Acquired‌5 Statements of Revenues and Direct Expenses‌6 Notes to Abbrevia
August 16, 2023	EX-99.3	Amphastar Pharmaceuticals, Inc. Unaudited Pro Forma Condensed Combined Financial Statements (amounts in thousands) Exhibit 99.3 Amphastar Pharmaceuticals, Inc. Unaudited Pro Forma Condensed Combined Financial Statements (amounts in thousands) On June 30, 2023, Amphastar Pharmaceuticals, Inc., or the Company, completed its acquisition of BAQSIMI® glucagon nasal powder, or BAQSIMI®, or the Acquisition, pursuant to an asset purchase agreement, or the Purchase Agreement, with Eli Lilly & Company, or Lilly, dated A
August 16, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 30, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 30, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Inco
August 9, 2023	EX-10.4	Credit Agreement dated June 30, 2023, by and between Amphastar Pharmaceuticals, Inc. and Wells Fargo Bank, National Association in the original sum of $700,000,000 (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023) Exhibit 10.4 CREDIT AGREEMENT dated as of June 30, 2023 among AMPHASTAR PHARMACEUTICALS, INC., as Borrower, The Subsidiaries of Borrower Party Hereto, as Guarantors, The Financial Institutions Party Hereto, as Lenders, and Wells Fargo Bank, National Association, as Administrative Agent, Swing Line Lender and L/C Issuer WELLS FARGO SECURITIES, LLC, CAPITAL ONE, NATIONAL ASSOCIATION, JPMORGAN CHASE
August 9, 2023	EX-10.1	Asset Purchase Agreement by and among Amphastar Pharmaceuticals, Inc., Amphastar Medication Co., LLC, and Eli Lilly and Company, dated April 21, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023) Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ASSET PURCHASE AGREEMENT BY AND AMONG ELI LILLY AND COMPANY, AMPHASTAR MEDICATION CO., LLC, AND Amphastar Pharmaceuticals, Inc. DATED AS OF APRIL 21, 2023 TABLE OF CONTENTS Pa
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH
August 9, 2023	EX-10.2	Manufacturing Service Agreement by and between Amphastar Pharmaceuticals, Inc., and Eli Lilly and Company, dated June 30, 2023 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023) Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED MANUFACTURING SERVICES AGREEMENT BETWEEN ELI LILLY AND COMPANY AND AMPHASTAR PHARMACEUTICALS, INC. DATED AS OF June 30, 2023 TABLE OF CONTENTS Page Article 1 DEFINITIONS; INTE
August 9, 2023	EX-10.3	Transition Service Agreement by and between Amphastar Pharmaceuticals, Inc., and Eli Lilly and Company, dated June 30, 2023 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023) Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TRANSITION SERVICES AGREEMENT BETWEEN ELI LILLY AND COMPANY AND AMPHASTAR PHARMACEUTICALS, INC. DATED AS OF June 30, 2023 TABLE OF CONTENTS Page Article I DEFINED TERMS‌1 Arti
August 8, 2023	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023 Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023 RANCHO CUCAMONGA, CA – August 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2023. Second Quarter Highlights ● Net
August 8, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 8, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
June 30, 2023	EX-99.1	2 Exhibit 99.1 Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly RANCHO CUCAMONGA, CA – June 30, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today announced that it has completed the previously announced acquisition of BAQSIMI® from Eli Lilly and Company (“Lilly”) (the “Acquisition”). Acquisition Highlights ● Provides Amphastar with a bran
June 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 30, 2023 Amphastar Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 30, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi
June 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2023 Amphastar Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2023 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP
May 9, 2023	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023 Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023 RANCHO CUCAMONGA, CA – May 9, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2023. First Quarter Highlights ● Net
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 9, 2023 Amphastar Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 9, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission
May 9, 2023	EX-10.1	Amendment to Contract Research Agreement by and between Amphastar Pharmaceuticals, Inc. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd., dated March 8, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2023) Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT TO THE CONTRACT RESEARCH AGREEMENT 委托开发协议之修订协议 This Amendment to the Contract Research Agreement (this “Amendment”) is entered into by and between the following part
April 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 21, 2023 Amphastar Pharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 21, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
April 24, 2023	EX-99.1	Lilly to Divest BAQSIMI to Amphastar Lilly focused on delivering the Company’s unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly’s mission to help more people benefit from BAQSIMI Exhibit 99.1 April 24, 2023 For Release:April 24, 2023 @ 6:45 a.m. ET Refer to:Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Dan Dischner; [email protected]; 909-942-4153 (Amphastar Media) Bill Peters; [email protected]; 909-476-3416 (Amphastar Investors) Lilly to Divest BAQSIMI to Amphastar Lilly focused on
April 14, 2023	DEFA14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻Definitive Pr
April 14, 2023	DEF 14A	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 8, 2023 Amphastar Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 8, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi
March 1, 2023	S-8	As filed with the Securities and Exchange Commission on March 1, 2023 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.
March 1, 2023	EX-21.1	Subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Amphastar France Pharmaceuticals, S.A.S. France Amphastar UK Limited United
March 1, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amphastar Pharmaceuticals, Inc.
March 1, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals,
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 28, 2023 Amphastar Pharm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 28, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm
February 28, 2023	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022 Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022 RANCHO CUCAMONGA, CA – February 28, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended Decembe
February 24, 2023	EX-3.1	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 24, 2023) Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF AMPHASTAR PHARMACEUTICALS, INC. (initially adopted on March 24, 2014) (as amended on February 23, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES‌1 1.1REGISTERED OFFICE‌1 1.2OTHER OFFICES‌1 ARTICLE II - MEETINGS OF STOCKHOLDERS‌1 2.1PLACE OF MEETINGS‌1 2.2ANNUAL MEETING‌1 2.3SPECIAL MEETING‌1 2.4ADVANCE NOTICE PROCEDURES‌2 2.5NOTICE OF STOCKHOL
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 23, 2023 Amphastar Pharm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 23, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm
February 9, 2023	SC 13G/A	AMPH / Amphastar Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Amphastar Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule
February 1, 2023	SC 13G/A	AMPH / Amphastar Pharmaceuticals Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Fili
January 27, 2023	SC 13G/A	AMPH / Amphastar Pharmaceuticals Inc / Zhang Jack Y. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
November 18, 2022	EX-10.1	Supply Agreement by and between Amphastar Nanjing Pharmaceuticals, Inc. and Nanjing Letop Biotechnology Co. Ltd. dated November 15, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 18, 2022) Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? SUPPLY AGREEMENT ? ???? ? This Supply Agreement (this ?Agreement?) is entered into by and between the following parties on November 15, 2022 (the ?Effective Date?): ??????
November 18, 2022	8-K	Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): November 15, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction o
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 8, 2022	EX-10.1	Contract Research Agreement by and between Amphastar Pharmaceuticals, Inc. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd., dated July 5, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 8, 2022) Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? CONTRACT RESEARCH AGREEMENT ?????? ? This Contract Research Agreement (this ?Agreement?) is entered into by and between the following parties on July 5, 2022 (the ?Effecti
November 7, 2022	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022 ? Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022 ? RANCHO CUCAMONGA, CA ? November 7, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended September 30, 2022. ? Third
November 7, 2022	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): November 7, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incor
August 9, 2022	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 4, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of I
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 9, 2022	EX-10.1	Contract Manufacturing Agreement by and between Amphastar Nanjing Pharmaceutical, Co. Ltd. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd, dated April 19, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2022) Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? ? CONTRACT MANUFACTURING AGREEMENT ? ?????? ? This Contract Manufacturing Agreement (this ?Agreement?) is entered into by and between the following parties on April 19, 20
August 8, 2022	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022 ? Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022 ? RANCHO CUCAMONGA, CA ? August 8, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended June 30, 2022. ? Second Quarter Highligh
August 8, 2022	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 8, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo
July 8, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): July 5, 2022 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissio
June 13, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2022 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) ? ? ? ? ? ? ? ? ? ? Delaware 001-36509 33-0702205 (State or other jurisdiction of i
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 9, 2022	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): May 9, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporat
May 9, 2022	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022 ? Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 ? RANCHO CUCAMONGA, CA ? May 9, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended March 31, 2022. ? First Quarter Highlight
April 22, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 19, 2022 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
April 14, 2022	DEF 14A	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?
April 14, 2022	DEFA14A	UNITED STATES DEFA14A 1 amph-20220414xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as p
March 11, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? ? ? ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2021 OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 001-36509 ?
March 11, 2022	S-8	As filed with the Securities and Exchange Commission on March 11, 2022 S-8 1 amph-20220311xs8.htm S-8 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AMPHASTAR PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 33-0702205 (State or other jurisdiction of
March 11, 2022	EX-21.1	Subsidiaries of the Company Exhibit 21.1 ? SUBSIDIARIES OF THE COMPANY ? ? ? ? ? ? ? ? State of ? Country of ? ? Incorporation/ ? Incorporation/ Company Name Organization Organization International Medication Systems, Limited ? California ? United States of America Armstrong Pharmaceuticals, Inc. ? Massachusetts ? United States of America Amphastar Nanjing Pharmaceuticals, Inc. ? ? ? China Amphastar France Pharmaceuticals, S
March 11, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 ? Calculation of Filing Fee Tables ? Form S-8 (Form Type) ? Amphastar Pharmaceuticals, Inc.
March 10, 2022	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): March 10, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo
March 10, 2022	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021 ? Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 ? RANCHO CUCAMONGA, CA ? March 10, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months and full-year ended Dece
February 14, 2022	SC 13G/A	AMPH / Amphastar Pharmaceuticals Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fili
February 11, 2022	SC 13G/A	AMPH / Amphastar Pharmaceuticals Inc / Zhang Jack Y. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
February 9, 2022	SC 13G/A	AMPH / Amphastar Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0255-amphastarpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Amphastar Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate
November 17, 2021	CORRESP	November 17, 2021 AMPHASTAR PHARMACEUTICALS, INC. 11570 6th Street, Rancho Cucamonga, CA 91730 ? Telephone: (909) 980-9484 ? Fax: (909) 481-6133 ? November 17, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Michael Davis Celeste Murphy ? Re: Amphastar Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed Novem
November 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 9, 2021	EX-10.1	Credit Agreement dated August 4, 2021, between Amphastar Pharmaceuticals, Inc. and Capital One N.A. in the original sum of $140,000,000 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2021) Exhibit 10.1 ? ? ? ? ? ? ? ? ? $140,000,000 CREDIT FACILITY ? ? ? CREDIT AGREEMENT ? ? Dated as of August 4, 2021 ? ? by and among ? AMPHASTAR PHARMACEUTICALS, INC., TOGETHER WITH THE OTHER PERSONS THAT ARE NOW OR FROM TIME TO TIME BECOME BORROWERS HEREUNDER, as Borrowers, ? THE OTHER PERSONS PARTY HERETO DESIGNATED FROM TIME TO TIME AS CREDIT PARTIES, ? CAPITAL ONE, NATIONAL ASSOCIATION, for itse
November 9, 2021	EX-4.3	Form of Indenture Exhibit 4.3 ? AMPHASTAR PHARMACEUTICALS, INC. INDENTURE Dated as of, 20 [] Trustee ? ? ? ? ? TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE?1 Section 1.1Definitions?1 Section 1.2Other Definitions?4 Section 1.3Incorporation by Reference of Trust Indenture Act?5 Section 1.4Rules of Construction?5 ARTICLE II THE SECURITIES?5 Section 2.1Issuable in Series?5 Section 2.2Esta
November 9, 2021	EX-10.2	Share Purchase Agreement by and between Amphastar Pharmaceuticals, Inc. and Nanjing Quanqia Enterprise Management Consulting, LLP, dated August 19, 2021 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2021) Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? ? ? ? ? Share Purchase Agreement ?????? ? ? ? ? ? August 19, 2021 2021 8?19? ? ? Share Purchase Agreement ?????? This Share Purchase Agreement (this ?Agreement?) is executed
November 9, 2021	S-3	As filed with the Securities and Exchange Commission on November 9, 2021 ? ? ? ? As filed with the Securities and Exchange Commission on November 9, 2021 Registration No.
November 8, 2021	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 ? Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021 ? RANCHO CUCAMONGA, CA ? November 8, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended September 30, 2021. ? Third
November 8, 2021	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): November 8, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incor
August 23, 2021	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 19, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of
August 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 19, 2021 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commis
August 10, 2021	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 5, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of I
August 9, 2021	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021 ? Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 ? RANCHO CUCAMONGA, CA ? August 9, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended June 30, 2021. ? Second Quarter Highligh
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 9, 2021	EX-10.3	Share Repurchase Agreement by and between Amphastar Pharmaceuticals, Inc., Nanjing Qianqia Enterprise Management Consulting (LLP), Nanjing Zhongpan Enterprise Management Consulting Center (LLP), and Nanjing Zhanrun Enterprise Management Consulting Center (LLP), dated May 6, 2021 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2021) Exhibit 10.3 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? Share Repurchase Agreement ?????? ? 2021?5?6? May 6, 2021 ? ? Share Repurchase Agreement ?????? This Share Repurchase Agreement (this ?Agreement?) is entered into on May 6
August 9, 2021	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 9, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo
August 9, 2021	EX-10.2	Share Purchase Agreement by and between Amphastar Pharmaceuticals, Inc., Nanjing Zhongpan Enterprise Management Consulting Center (LLP), Nanjing Zhanrun Enterprise Management Consulting Center (LLP), and Listening Dragon Investment Company Limited, dated May 6, 2021 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2021) Exhibit 10.2 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Share Purchase Agreement ?????? ? May 6, 2021 2021?5?6? ? ? Share Purchase Agreement ?????? This Share Purchase Agreement (this ?Agreement?) is executed on May 6, 2021 by th
August 9, 2021	EX-10.1	Sixth Amendment to the Supply Agreement by and between MannKind Corporation and Amphastar Pharmaceuticals, Inc., dated May 24, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2021) Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ? SIXTH AMENDMENT TO SUPPLY AGREEMENT This sixth amendment (?Sixth Amendment?) to the Supply Agreement by and between MannKind Corporation (?MannKind?) and Amphastar Pharma
August 9, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 4, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of I
June 8, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2021 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) ? ? ? ? ? ? ? ? ? ? Delaware 001-36509 33-0702205 (State or other jurisdiction of in
May 7, 2021	10-Q	Quarterly Report - 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 7, 2021	EX-99.1	Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary Exhibit 99.1 Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary ? RANCHO CUCAMONGA, CA ? May 7, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (?ANP?). As part of the restructuring, Amphastar will buyback 26% of ANP?s equity current
May 7, 2021	DEFA14A	- DEFA14A ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy
May 7, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): May 6, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Inco
May 6, 2021	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): May 6, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporat
May 6, 2021	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021 ? Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021 ? RANCHO CUCAMONGA, CA ? May 6, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended March 31, 2021. ? First Quarter Highlight
April 14, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?
April 14, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?Definitive Pr
March 15, 2021	EX-4.2	Description of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.2 to the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2021) Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following information describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This description is only a summary and does not purport to be complete. It is su
March 15, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? ? ? ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2020 OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 001-36509 ?
March 15, 2021	EX-10.40	Eight Modification to the Revolving Line of Credit Agreement, dated March 7, 2016, between International Medication Systems, Limited and East West Bank in the principal sum of $15,000,000. Exhibit 10.40 ? ? ? EIGHTH MODIFICATION TO THE LOAN AGREEMENT ? Borrower: International Medication Systems, Limited ? Lender: East West Bank ? 11570 6th Street ? Loan Servicing Department ? Rancho Cucamonga, CA 91730 ? 9300 Flair Drive, 6th Floor ? ? ? ? ? El Monte, CA 91731 ? This EIGHTH MODIFICATION TO THE LOAN AGREEMENT is attached to and by this reference is made a part of the Business Loan Ag
March 15, 2021	EX-21.1	Subsidiaries of the Company Exhibit 21.1 ? SUBSIDIARIES OF THE COMPANY ? ? ? ? ? ? ? ? State of ? Country of ? ? Incorporation/ ? Incorporation/ Company Name Organization Organization International Medication Systems, Limited ? California ? United States of America Armstrong Pharmaceuticals, Inc. ? Massachusetts ? United States of America Amphastar Nanjing Pharmaceuticals, Inc. ? ? ? China Nanjing Letop Biological Technology
March 15, 2021	EX-99.1	Three Months Ended EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020 ? Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 ? RANCHO CUCAMONGA, CA ? March 15, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months and full-year ended Decem
March 15, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 15, 2021 Registration No.
March 15, 2021	8-K	Current Report ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): March 15, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo
February 12, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _____) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) (CUSIP OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filin
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Cla UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Amphastar Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule
January 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): January 12, 2021 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi
January 12, 2021	EX-99.1	1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management’s current expectations and assumptions and on information currently available to management. For Exhibit 99.1 Investor Presentation January 2021 Exhibit 99.1 1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact c
November 6, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 3, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi
November 6, 2020	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 RANCHO CUCAMONGA, CA – November 6, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2020. Third Quarter H
November 6, 2020	EX-10.1	Equipment Line of Credit, dated September 1, 2020, between International Medication Systems, Limited and East West Bank in the original sum of $10,000,000. (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 6, 2020) Exhibit 10.1 PROMISSORY NOTE Borrower: International Medication Systems, Limited Lender: East West Bank 11570 6th Street Loan Servicing Department Rancho Cucamonga, CA 91730 9300 Flair Drive, 6th Floor El Monte, CA 91731 Principal Amount: $10,000,000.00 Date of Note: September 1, 2020 PROMISE TO PAY. INTERNATIONAL MEDICATION SYSTEMS, LIMITED ("Borrower") promises to pay to East West Bank ("Lender"
November 6, 2020	EX-99.1	AMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN Exhibit 99.1 AMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are: ●to attract and retain the best available personnel for positions of substantial responsibility, ●to provide additional incentive to Employees, Directors and Consultants, and ●to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock O
November 6, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509
November 6, 2020	8-K	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 6, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi
August 10, 2020	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2020 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Comm
August 10, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH
August 10, 2020	EX-10.1	Separation Agreement and General Release of Claims by and between the Amphastar Pharmaceuticals, Inc. and Jason Shandell dated as of April 13, 2020. (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2020) Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This Separation Agreement and General Release of Claims (“Agreement”) is freely entered into by Jason Shandell (“Shandell”), and Amphastar Pharmaceuticals, Inc. (the “Company”). (All of the parties are referred to herein collectively as the “parties”.) RECITALS Whereas, Shandell and the Company entered into that certain employment agr
August 10, 2020	EX-10.2	Eighth Modification to the Revolving Line of Credit Agreement, dated June 15, 2020, between Amphastar Pharmaceuticals, Inc. and Armstrong Pharmaceuticals, Inc. and Cathay Bank in the principal sum of $20,000,000. (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2020) Exhibit 10.2 Loan No.: 2000017069-100 EIGHTH MODIFICATION AGREEMENT THIS EIGHTH MODIFICATION AGREEMENT (“Modification”) is dated as of this 15th day of June, 2020, by and among AMPHASTAR PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”) and ARMSTRONG PHARMACEUTICALS, INC., a Delaware corporation (“Guarantor”), on the one hand, and CATHAY BANK, a California banking corporation (“Lender”),
August 6, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 6, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
August 6, 2020	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2020 Reports Net Revenues of $85.8 Million for the Three Months Ended June 30, 2020 RANCHO CUCAMONGA, CA – August 6, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2020. Second Quarter Highlights ● Net
June 9, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2020 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis
May 11, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP
May 7, 2020	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2020 Reports Net Revenues of $84.7 Million for the Three Months Ended March 31, 2020 RANCHO CUCAMONGA, CA – May 7, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2020. First Quarter Highlights · Net r
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 7, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission
April 15, 2020	DEF 14A	AMPH / Amphastar Pharmaceuticals, Inc. DEF 14A - - DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defi
April 15, 2020	DEFA14A	AMPH / Amphastar Pharmaceuticals, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐Definitive Pr
April 14, 2020	EX-99.1	Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure Exhibit 99.1 Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure RANCHO CUCAMONGA, CA – April 13, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceutical company, today announces a recent simplification of the Company’s management by removing a layer of management in the organizational
April 14, 2020	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 10, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Inc
April 13, 2020	EX-99.1	Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure Exhibit 99.1 Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure RANCHO CUCAMONGA, CA – April 13, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceutical company, today announces a recent simplification of the Company’s management by removing a layer of management in the organizational
April 13, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 13, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
March 16, 2020	EX-4.2	Description of Securities Registered Under Section 12 of the Exchange Act Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following information describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This description is only a summary and does not purport to be complete. It is subj
March 16, 2020	EX-10.39	Amphastar Pharmaceuticals, Inc. Employee Deferred Compensation Plan, effective December 1, 2019. (incorporated by reference to Exhibit 10.39 to the Company’s Annual Report on Form 10-K filed with the SEC on March 16, 2020) Exhibit 10.39 AMPHASTAR PHARMACEUTICALS, INC. DEFERRED COMPENSATION PLAN Effective Date December 1, 2019 Amphastar Pharmaceuticals, Inc. Deferred Compensation Plan ARTICLE I Establishment and Purpose 1 ARTICLE II Definitions 1 ARTICLE III Eligibility and Participation 7 ARTICLE IV Deferrals 7 ARTICLE V Company Contributions 11 ARTICLE VI Payments from Accounts 12 ARTICLE VII Valuation of Account B
March 16, 2020	S-8	AMPH / Amphastar Pharmaceuticals, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on March 16, 2020 Registration No.
March 16, 2020	10-K	The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 16, 2020 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals,
March 16, 2020	EX-21.1	Subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Nanjing Letop Fine Chemistry Co., Ltd. China Nanjing Hanxin Medical Technol
March 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 12, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
March 12, 2020	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019 Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, CA – March 12, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31
February 14, 2020	SC 13G/A	AMPH / Amphastar Pharmaceuticals, Inc. / Zhang Jack Y. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
February 11, 2020	SC 13G	AMPH / Amphastar Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Amphastar Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-
November 8, 2019	10-Q	AMPH / Amphastar Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509
November 7, 2019	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2019 Reports Net Revenues of $80.1 Million for the Three Months Ended September 30, 2019 RANCHO CUCAMONGA, CA – November 7, 2019 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2019. Third Quarter H
November 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 7, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi
August 9, 2019	EX-10.1	Ninth Amendment to the Acquisition Loan, dated July 19, 2019 between Amphastar Pharmaceuticals, Inc. and Cathay Bank. (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2019) Exhibit 10.1 Loan No.: 3000029918-100 NINTH AMENDMENT TO LOAN AGREEMENT AND OTHER LOAN DOCUMENTS, AND SECOND EXTENSION AGREEMENT This Ninth Amendment to Loan Agreement and Other Loan Documents, and Second Extension Agreement (the “Amendment”) dated as of July 19, 2019 (“Reference Date”), which is effective as of June 22, 2019 (“Effective Date”), is between AMPHASTAR PHARMACEUTICALS, INC., a Delawa
August 9, 2019	EX-10.2	Fifth Amendment to the Supply Agreement by and between MannKind Corporation and Amphastar Pharmaceuticals, Inc., dated August 2, 2019. (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2019) Exhibit 10.2 Certain identified information has been omitted from this document because it is not material and would be competitively harmful if publicly disclosed, and has been marked with “[***]” to indicate where omissions have been made. FIFTH AMENDMENT TO SUPPLY AGREEMENT This fifth amendment (“Fifth Amendment”) to the Supply Agreement by and between MannKind Corporation (“MannKind”) and Amph
August 9, 2019	10-Q	AMPH / Amphastar Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH
August 7, 2019	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2019 Reports Net Revenues of $79.0 Million for the Three Months Ended June 30, 2019 RANCHO CUCAMONGA, CA – August 7, 2019 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2019. Second Quarter Highlights · Net
August 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
June 19, 2019	EX-99.1	Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz Exhibit 99.1 Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz RANCHO CUCAMONGA, CA – June 19, 2019 – Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) today announced that it has entered into a settlement agreement (the “Settlement Agreement”) with Momenta Pharmaceuticals Inc. and Sandoz Inc., (collectively, “Momenta/Sandoz”). Under the terms of the Settleme
June 19, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 19, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi
June 13, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2019 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commi
May 10, 2019	10-Q	AMPH / Amphastar Pharmaceuticals, Inc. 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP
May 10, 2019	EX-10.1	Equipment Line of Credit, dated January 8, 2019, between International Medication Systems, Limited and East West Bank in the original principal sum of $10,000,000. (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 10, 2019) Exhibit 10.1 CORPORATE RESOLUTION TO GRANT COLLATERAL / GUARANTEE Borrower: International Medication Systems, Limited Lender: East West Bank 11570 6th Street Loan Servicing Department Rancho Cucamonga, CA 91730 9300 Flair Drive, 6th Floor El Monte, CA 91731 Corporation: Amphastar Pharmaceuticals, Inc. 11570 6th Street Rancho Cucamonga, CA 91730 I, THE UNDERSIGNED, DO HEREBY CERTIFY THAT: THE CORPO
May 10, 2019	EX-10.2	First Modification to the Loan Agreement, dated April 22, 2019, between Amphastar Pharmaceuticals, Inc. and Cathay Bank. (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 10, 2019) Exhibit 10.2 FIRST EXTENSION AGREEMENT ($21.9M Term Loan) This FIRST EXTENSION AGREEMENT ($21.9M Term Loan) (the “Extension”) dated as of April 22, 2019, is between AMPHASTAR PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), and ARMSTRONG PHARMACEUTICALS, INC., a Delaware corporation (“Guarantor”), on the one hand, and CATHAY BANK, a California banking corporation (“Lender”), on the othe
May 9, 2019	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019 Reports Net Revenues of $79.8 Million for the Three Months Ended March 31, 2019 RANCHO CUCAMONGA, CA – May 9, 2019 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2019. First Quarter Highlights · Net r
May 9, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 9, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission
April 18, 2019	DEFA14A	AMPH / Amphastar Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐Definitive Pr
April 18, 2019	DEF 14A	AMPH / Amphastar Pharmaceuticals, Inc. DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defi
March 15, 2019	S-8	AMPH / Amphastar Pharmaceuticals, Inc. S-8 As filed with the Securities and Exchange Commission on March 15, 2019 Registration No.
March 15, 2019	10-K	AMPH / Amphastar Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals,
March 15, 2019	EX-21.1	Subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Nanjing Letop Fine Chemistry Co., Ltd. China Nanjing Hanxin Medical Technol
March 15, 2019	EX-10.45	Fourth Amendment to Supply Agreement, dated December 24, 2018, by and between MannKind Corporation and Amphastar Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.45 to the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2018) Exhibit 10.45 FOURTH AMENDMENT TO SUPPLY AGREEMENT This fourth amendment (“Fourth Amendment”) to the Supply Agreement by and between MannKind Corporation (“MannKind”) and Amphastar Pharmaceuticals, Inc. (“Amphastar”), originally dated July 31, 2014 and as previously amended on October 31, 2014, November 9, 2016 and April 11, 2018 (collectively, the “Agreement”), is hereby made as of the 24 day of
March 14, 2019	DEFA14A	AMPH / Amphastar Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 8, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi
March 14, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 8, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi
March 12, 2019	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018 Reports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018 RANCHO CUCAMONGA, CA – March 12, 2019 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31
March 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 12, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
February 13, 2019	SC 13G/A	AMPH / Amphastar Pharmaceuticals, Inc. / Zhang Jack Y. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
November 16, 2018	CORRESP	AMPH / Amphastar Pharmaceuticals, Inc. CORRESP AMPHASTAR PHARMACEUTICALS, INC. 11570 6th Street, Rancho Cucamonga, CA 91730 • Telephone: (909) 980-9484 • Fax: (909) 481-6133 November 16, 2018 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Suzanne Hayes Jeffrey Gabor Re: Amphastar Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 9
November 9, 2018	EX-4.4	Form of Subordinated Debt Security (included in Exhibit 4.4) Exhibit 4.4 AMPHASTAR PHARMACEUTICALS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions 1 Section 1.2 Compliance Certificates and Opinions 9 Section 1.3 Form of Documents Delivered to Trustee 10 Section 1.4 Acts of Holders; Record Dates 10 Section 1.5 Notices
November 9, 2018	EX-4.2	Form of Senior Debt Security (included in Exhibit 4.2) Exhibit 4.2 AMPHASTAR PHARMACEUTICALS, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 2 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 2.1 Definitions 1 Section 2.2 Compliance Certificates and Opinions 8 Section 2.3 Form of Documents Delivered to Trustee 8 Section 2.4 Acts of Holders; Record Dates 9 Section 2.5 Notices, etc.,
November 9, 2018	S-3	AMPH / Amphastar Pharmaceuticals, Inc. S-3 As filed with the Securities and Exchange Commission on November 9, 2018 Registration No.
November 9, 2018	10-Q	AMPH / Amphastar Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509
November 8, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 8, 2018 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi
November 8, 2018	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2018 Reports Net Revenues of $75.5 Million for the Three Months Ended September 30, 2018 RANCHO CUCAMONGA, CA – November 8, 2018 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2018. Third Quarter H
November 8, 2018	EX-99.1	Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene Exhibit 99.1 Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene® MIST Primatene® MIST fills unmet medical need as the only FDA approved over-the-counter asthma inhaler RANCHO CUCAMONGA, CA – November 7, 2018 – Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (FDA) granted approval of its New Drug Application (NDA) for Pri
November 8, 2018	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2018 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Co
August 9, 2018	EX-10.5	Subscription Agreement between Amphastar Cayman, LLC and Stephen B. Shohet dated June 28, 2018 Exhibit 10.5 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	EX-10.6	Subscription Agreement between Amphastar Cayman, LLC and Chieh-Lin J. Lee dated June 28, 2018 Exhibit 10.6 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	EX-10.3	Subscription Agreement between Amphastar Cayman, LLC and Rong Zhou dated June 28, 2018 Exhibit 10.3 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	EX-10.7	Subscription Agreement between Amphastar Cayman, LLC and Yu-Chieh W. Lee dated June 28, 2018 Exhibit 10.7 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	EX-10.8	Subscription Agreement between Amphastar Cayman, LLC and KYW Investment partnership dated June 28, 2018 Exhibit 10.8 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	10-Q	AMPH / Amphastar Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH
August 9, 2018	EX-10.4	Subscription Agreement between Amphastar Cayman, LLC and Yakob Liawatidewi dated June 28, 2018 Exhibit 10.4 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	EX-10.2	Subscription Agreement between Amphastar Cayman, LLC and William J. Peters dated June 28, 2018 Exhibit 10.2 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	EX-10.1	Subscription Agreement between Amphastar Cayman, LLC and Jason B. Shandell dated June 28, 2018 Exhibit 10.1 SUBSCRIPTION MATERIALS AMPHASTAR CAYMAN a Cayman Islands limited liability company These subscription materials (the “Subscription Materials”) set out representations, warranties and undertakings required to be made in connection with an investment in Amphastar Cayman, a Cayman Islands limited liability company (the “Company”). Any investment in the Company may be approved or disappro
August 9, 2018	EX-10.9	Partnership Agreement by and between Zhang Chongqing, Bill Zhang and Applied Physics & Chemistry Laboratories, Inc. dated July 27, 2018. (incorporated by reference to Exhibit 10.9 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2018) Exhibit 10.9 Nanjing Qianqia Enterprise Management Consulting Center (Limited Partnership) Partnership Agreement After a consensus has been reached through negotiation, the Partnership Agreement (hereinafter referred to as "the Agreement") is hereby concluded by the general partner and limited partners of the Partnership Enterprise (Limited Partnership) for abidance. Chapter IGeneral Article 1 In
August 8, 2018	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018 Reports Net Revenues of $71.0 Million for the Three Months Ended June 30, 2018 RANCHO CUCAMONGA, CA – August 8, 2018 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2018. Second Quarter Highlights · Net
August 8, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 8, 2018 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss
July 9, 2018	8-K	Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 2, 2018 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis
July 9, 2018	EX-99.1	Amphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc. Exhibit 99.1 Amphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc. RANCHO CUCAMONGA, CA – July 9, 2018 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). To date, ANP has provided Active Pharmaceutical Ingredients (“APIs”) and starting materials specifically to Amphastar. After th
June 8, 2018	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2018 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis
May 9, 2018	10-Q	AMPH / Amphastar Pharmaceuticals, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2018 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP
May 9, 2018	EX-99.1	Three Months Ended EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018 Reports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018 RANCHO CUCAMONGA, CA – May 9, 2018 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2018. First Quarter Highlights · Net r
May 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 9, 2018 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission
April 18, 2018	DEFA14A	AMPH / Amphastar Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐Definitive Pr
April 18, 2018	DEF 14A	AMPH / Amphastar Pharmaceuticals, Inc. DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defi

AMPH / Amphastar Pharmaceuticals, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)

Other Listings